Group One Trading’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-11,452
Closed -$1.19M 7955
2025
Q1
$1.01M Sell
11,452
-35,742
-76% -$3.49M ﹤0.01% 2455
2024
Q4
$4.12M Sell
47,194
-3,267
-6% -$299K 0.01% 1308
2024
Q3
$4.67M Buy
+50,461
New +$5.01M 0.01% 1055
2023
Q4
Sell
-53,858
Closed -$3.49M 7411
2023
Q3
$2.7M Buy
53,858
+27,583
+105% +$1.47M 0.01% 1391
2023
Q2
$1.66M Buy
26,275
+14,671
+126% +$798K 0.01% 1890
2023
Q1
$522K Buy
11,604
+5,228
+82% +$236K ﹤0.01% 2741
2022
Q4
$279K Buy
6,376
+1,704
+36% +$81.7K ﹤0.01% 3563
2022
Q3
$308K Buy
4,672
+4,416
+1,725% +$284K ﹤0.01% 3708
2022
Q2
$13K Buy
+256
New +$15K ﹤0.01% 6592
2022
Q1
Sell
-1,500
Closed -$108K 8041
2021
Q4
$161K Sell
1,500
-4,000
-73% -$418K ﹤0.01% 5294
2021
Q3
$565K Buy
5,500
+5,067
+1,170% +$472K ﹤0.01% 4043
2021
Q2
$38K Buy
433
+100
+30% +$9.16K ﹤0.01% 6787
2021
Q1
$32K Buy
+333
New +$33.2K ﹤0.01% 6498
2020
Q1
Sell
-8,167
Closed -$526K 5270
2019
Q4
$654K Buy
8,167
+5,324
+187% +$399K ﹤0.01% 2219
2019
Q3
$209K Buy
+2,843
New +$246K ﹤0.01% 3042
2019
Q1
Sell
-7,158
Closed -$386K 4818
2018
Q4
$386K Buy
7,158
+3,883
+119% +$236K ﹤0.01% 2169
2018
Q3
$256K Sell
3,275
-2,534
-44% -$176K ﹤0.01% 2834
2018
Q2
$369K Buy
+5,809
New +$462K ﹤0.01% 2555
2017
Q2
Sell
-2,781
Closed -$111K 4749
2017
Q1
$111K Buy
2,781
+2,024
+267% +$72.5K ﹤0.01% 2904
2016
Q4
$21K Buy
757
+606
+401% +$18.3K ﹤0.01% 3681
2016
Q3
$4K Sell
151
-749
-83% -$18.6K ﹤0.01% 4250
2016
Q2
$18K Hold
900
﹤0.01% 3831
2016
Q1
$16K Buy
+900
New +$15.6K ﹤0.01% 3843

Other funds holding BPMC

Group One Trading's BPMC Position: Q2 2025 in Review

Group One Trading sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 11,452 shares — an estimated $1.19M sold.

Group One Trading first reported a position in BPMC in Q1 2016 and held it in 23 quarters. The position peaked at $4.67M in Q3 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Group One Trading reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Group One Trading sold 11,452 Blueprint Medicines shares in Q2 2025, an estimated $1.19M.
  • Group One Trading first reported a position in Blueprint Medicines in Q1 2016 and held it in 23 quarters.
  • Group One Trading's Blueprint Medicines position peaked at $4.67M in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.